Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 20/20 | 0.68 |
| ▸ | MMP13 | P45452 | 15/20 | 0.68 |
| ▸ | MMP8 | P22894 | 2/20 | 0.68 |
| ▸ | MMP2 | P08253 | 1/20 | 0.68 |
| ▸ | MMP1 | P03956 | 10/20 | 0.52 |
| ▸ | MMP9 | P14780 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13779537 | 0.86 | KMT2A (0.60) | — | |
| SCHEMBL8334567 | 0.82 | ADAM17 (0.77) | ADAM17MMP13MMP8MMP2MMP1 | |
| SCHEMBL8199226 | 0.82 | PKM (0.58) | MMP13MMP8MMP2MMP1MMP9 | |
| SCHEMBL12708189 | 0.81 | ADAM17 (1.00) | ADAM17MMP13MMP8MMP2MMP1 | |
| SCHEMBL8334970 | 0.81 | ADAM17 (1.00) | ADAM17MMP13MMP8MMP2MMP1 | |
| SCHEMBL8329165 | 0.81 | ADAM17 (1.00) | ADAM17MMP13MMP8MMP2MMP1 | |
| SCHEMBL7313611 | 0.80 | ADAM17 (0.65) | ADAM17MMP13MMP8MMP2MMP1 | |
| SCHEMBL12730546 | 0.78 | EPHX2 (0.46) | — | |
| SCHEMBL8334839 | 0.77 | ADAM17 (1.00) | ADAM17MMP13MMP8MMP2MMP1 | |
| SCHEMBL21067889 | 0.76 | ADAM17 (0.73) | ADAM17MMP13MMP8MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919520-B2 | Inhibitors of tace | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-05 | — | — | US | disclosed |
| EP-1581488-B1 | INHIBITORS OF TACE | VERTEX PHARMA (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20090176782-A1 | INHIBITORS OF TACE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-7485664-B2 | Inhibitors of TACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-03 | — | — | US | disclosed |
| WO-2004056766-A1 | INHIBITORS OF TACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176782-A1 | INHIBITORS OF TACE | HDGF, ADAM17, PCSK9 | ADAM17 2/4885MMP13 84/4885MMP8 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.